Table 1

Demographic and clinical characteristics of PMR patients, total controls and RA patients*

	PMR patients (n=136)	Total control group (n=149)	RA patients (n=94)	p (1 vs 2)	p (1 vs 3)
Age, years, mean±SD	74±7.5	64±9.9	65.4±10	<0.001	<0.001
Age >65 years	89	47	53	<0.001	<0.001
Sex (M/F)	29.6/70.4	28.6/71.4	27/73	NS	NS
Duration of symptoms, weeks, mean±SD	12.9±10	13.3±11	12.4±10.5	NS	NS
ESR, mm/h, mean±SD	60±24	29±24	38±26	<0.001	<0.001
ESR >40 mm/h	79	26.9	38.5	<0.001	<0.001
CRP, mg/dl, mean±SD	5.09±4.26	1.73±2.44	2.27±2.61	<0.001	<0.001
CRP >0.5, mg/dL	98.5	54.1	71.9	<0.001	<0.001
Positive RF (>40 UI/mL)	2.2	25.6	41.7	<0.001	<0.001
Positive ACPA† (>40 U/mL)	1.4	27.3	41.6	<0.001	<0.001
Morning stiffness, min, mean±SD	164±109	62±74	85±81	<0.001	<0.001
Peripheral joint involvement	38.2‡	91.8	99	<0.001	<0.001

*Values are percentage unless specified.
†ACPA were determined in 69 PMR patients.
‡88% had monoarthritis or oligoarthritis involving knee, ankle and/or wrist.
ACPA, anticitrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; RF, rheumatoid factor.